Quest Diagnostics (DGX) Q4 2010 Earnings Call January 25, 2011 8:30 am ET Executives Kathleen Valentine - Director of Investor Relations Robert Hagemann - Chief Financial Officer and Senior Vice President Surya Mohapatra - Chairman, Chief Executive Officer, President and Chairman of Executive Committee Analysts William Quirk - Piper Jaffray Companies Ralph Giacobbe - Crédit Suisse AG Jason Gurda - Leerink Swann LLC Shelley Gnall-Sazenski Ricky Goldwasser - Morgan Stanley Steven Valiquette - UBS Investment Bank Gary Lieberman - Wells Fargo Securities, LLC Arthur Henderson - Jefferies & Company, Inc. Robert Willoughby Thomas Gallucci - Lazard Capital Markets LLC Anthony Vendetti Darren Lehrich - Deutsche Bank AG Brendan Strong - Barclays Capital Gary Taylor - Citigroup Inc Adam Feinstein - Barclays Capital Dawn Brock - Kaufman Bros., L.P. Amanda Murphy - William Blair & Company L.L.C. Bill Bonello - RBC Capital Markets, LLC PresentationOperator
Welcome to the Quest Diagnostics Fourth Quarter and Full Year Conference Call. [Operator Instructions] Now, I'd like to introduce Kathleen Valentine, Director of Investor Relations for Quest Diagnostics. Go ahead, please. Kathleen Valentine Thank you, and good morning. I am here with Surya Mohapatra, our Chairman and Chief Executive Officer; and Bob Hagemann, our Chief Financial Officer. Some of our commentary and answers to questions may contain forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigation; lawsuits or private actions; the competitive environment; changes in government regulations; changing relationships with customers, payers, suppliers and strategic partners; and other factors described in the Quest Diagnostics' 2009 Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.